How the latest AI‑driven drug discovery platforms are helping biopharma teams accelerate R&D, improve decision‑making, and deliver more precise therapies across diverse disease areas

Description

Artificial intelligence is accelerating innovation across the drug discovery pipeline—from predicting novel molecular structures to guiding preclinical experiments and optimizing development strategies. This panel brings together leading AI drug discovery platform founders and the biotech companies that deploy these tools to develop therapies across oncology, neurology, rare diseases, aging, and autoimmune conditions. We’ll explore how AI-driven approaches are transforming therapeutic R&D, enabling smarter decisions, reducing timelines, and opening new possibilities for treatments that were once out of reach.

Speakers

Vinicio Vargas

Co-founder and CEO, Ainnova Tech

Krishna Bulusu

VP of Product, Turbine

Guided Questions

Vinicio Vargas

Through Ainnova Tech, you have pioneered AI-driven preventive screening programs across Latin America to detect conditions like diabetic retinopathy and cardiovascular risk early. How can preventive screening both improve patient outcomes and help the industry identify target populations, accelerate clinical trials, and bring new therapies to market more effectively?

Krishna Bulusu

With your experience applying AI and computational biology to oncology and now leading product strategy at Turbine, how do you see AI transforming the drug discovery pipeline—from identifying targets to selecting combinations—and what breakthroughs are needed to move these tools from promising models to real clinical impact?